PROPHYLACTIC NAPROXEN OR LORATADINE FOR BONE PAIN IN PATIENTS WITH BREAST CANCER RECEIVING CHEMOTHERAPY AND PEGFILGRASTIM: A RANDOMIZED, PHASE 2 STUDY (NOLAN) AMGEN 20110147; NCT 01712009.

被引：0
|
作者：
Guinigundo, Andrew S. [1 ]
Maxwell, Cathy [2 ]
Vanni, Linda [3 ]
Watson, Holly [4 ]
Badre, Sejal [5 ]
Kirshner, Jeffrey J. [6 ]
机构：
[1] Oncol Hematol Care Inc, Cincinnati, OH USA
[2] Adv Med Specialties, Miami, FL USA
[3] Providence Hosp, Southfield, MI 48037 USA
[4] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA
[5] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
[6] Hematol Oncol Associates Cent New York, East Syracuse, NY USA
来源：
ONCOLOGY NURSING FORUM | 2013年 / 40卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E429 / E429
页数：1
相关论文
共 50 条
  • [31] An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy
    Wei Zhang
    Zhiwei Jiang
    Ling Wang
    Chanjuan Li
    Jielai Xia
    Medical Oncology, 2015, 32
  • [32] An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy
    Zhang, Wei
    Jiang, Zhiwei
    Wang, Ling
    Li, Chanjuan
    Xia, Jielai
    MEDICAL ONCOLOGY, 2015, 32 (05) : 1 - 7
  • [33] Advantages of prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: An open-label, randomized, multicenter phase III study
    Xie, Jie
    Cao, Jun
    Wang, Zhonghua
    Wang, Biyun
    Zhang, Sheng
    Wang, Leiping
    Zhang, Jian
    Tao, Zhonghua
    Li, Ting
    Zhang, JinFeng
    Hu, Xi-Chun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
    Jie Xie
    Jun Cao
    Jing-fen Wang
    Bai-hong Zhang
    Xiao-hua Zeng
    Hong Zheng
    Yang Zhang
    Li Cai
    Yu-dong Wu
    Qiang Yao
    Xiao-chun Zhao
    Wei-dong Mao
    Ai-Mei Jiang
    Shao-shui Chen
    Shun-e Yang
    Shu-sen Wang
    Jian-hong Wang
    Yue-yin Pan
    Bi-yong Ren
    Yan-ju Chen
    Li-zhi Ouyang
    Kai-jian Lei
    Jing-hua Gao
    Wen-he Huang
    Zhan Huang
    Tao Shou
    Yan-ling He
    Jing Cheng
    Yang Sun
    Wei-ming Li
    Shu-de Cui
    Xin Wang
    Zhi-guo Rao
    Hu Ma
    Wei Liu
    Xue-yong Wu
    Wei-xi Shen
    Fei-lin Cao
    Ze-min Xiao
    Biao Wu
    Shu-yan Tian
    Dong Meng
    Peng Shen
    Bi-yun Wang
    Zhonghua Wang
    Jian Zhang
    Leiping Wang
    Xi-chun Hu
    Breast Cancer Research and Treatment, 2018, 168 : 389 - 399
  • [35] Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
    Xie, Jie
    Cao, Jun
    Wang, Jing-fen
    Zhang, Bai-hong
    Zeng, Xiao-hua
    Zheng, Hong
    Zhang, Yang
    Cai, Li
    Wu, Yu-dong
    Yao, Qiang
    Zhao, Xiao-chun
    Mao, Wei-dong
    Jiang, Ai-Mei
    Chen, Shao-shui
    Yang, Shun-e
    Wang, Shu-sen
    Wang, Jian-hong
    Pan, Yue-yin
    Ren, Bi-yong
    Chen, Yan-ju
    Ouyang, Li-zhi
    Lei, Kai-jian
    Gao, Jing-hua
    Huang, Wen-he
    Huang, Zhan
    Shou, Tao
    He, Yan-ling
    Cheng, Jing
    Sun, Yang
    Li, Wei-ming
    Cui, Shu-de
    Wang, Xin
    Rao, Zhi-guo
    Ma, Hu
    Liu, Wei
    Wu, Xue-yong
    Shen, Wei-xi
    Cao, Fei-lin
    Xiao, Ze-min
    Wu, Biao
    Tian, Shu-yan
    Meng, Dong
    Shen, Peng
    Wang, Bi-yun
    Wang, Zhonghua
    Zhang, Jian
    Wang, Leiping
    Hu, Xi-chun
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 389 - 399
  • [36] Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
    Desai, Kalpna
    Misra, Priya
    Kher, Sanyukta
    Shah, Nirmesh
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
  • [37] Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
    Kalpna Desai
    Priya Misra
    Sanyukta Kher
    Nirmesh Shah
    Experimental Hematology & Oncology, 7
  • [38] Halt-d: A randomized open label phase 2 study of crofelemer for the prevention of chemotherapy induced diarrhea (cid) in patients with breast cancer receiving trastuzumab, pertuzumab, and a taxane
    Pohlmann, Paula R.
    Graham, Deena
    Wu, Tianmin
    Ottaviano, Yvonne
    Mohebtash, Mahsa
    Kurian, Shweta
    McNamara, Donna
    Lynce, Filipa
    Warren, Robert
    Dilawari, Asma
    Rao, Suman
    Mainor, Candace
    Swanson, Nicole
    Tan, Ming
    Isaacs, Claudine
    Swain, Sandra M.
    CANCER RESEARCH, 2022, 82 (04)
  • [39] Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase II, randomized, controlled study
    Hecht, J. R.
    Pillai, M.
    Gollard, R.
    Dreiling, L.
    Mo, M.
    Malik, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Phase 2 randomized study of a walking intervention for radiation-related fatigue among older breast cancer patients receiving radiation.
    VanderWalde, Noam Avraham
    Martin, Michelle Y.
    Kocak, Mehmet
    Morningstar, Catherine
    Deal, Allison Mary
    Nyrop, Kirsten A.
    Farmer, Michael
    Ballo, Matthew T.
    Schwartz, David L.
    Muss, Hyman B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345